Study Identifies How COVID-19 Linked to Alzheimer’s Disease-like Cognitive Impairment

A new Cleveland Clinic-led study has identified mechanisms by which COVID-19 can lead to Alzheimer’s disease-like dementia. The findings, published in Alzheimer’s Research & Therapy, indicate an overlap between COVID-19 and brain changes common in Alzheimer’s, and may help inform risk management and therapeutic strategies for COVID-19-associated cognitive impairment.

Memory Biomarkers Confirm Aerobic Exercise Helps Cognitive Function in Older Adults

Until now, systemic biomarkers to measure exercise effects on brain function and that link to relevant metabolic responses were lacking. A study shows a memory biomarker, myokine Cathepsin B (CTSB), increased in older adults following a 26-week structured aerobic exercise training. The positive association between CTSB and cognition, and the substantial modulation of lipid metabolites implicated in dementia, support the beneficial effects of exercise training on brain function and brain health in asymptomatic individuals at risk for Alzheimer’s.

Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine

NEWS STORIES IN THIS ISSUE:
– Study Says Failure to Rid Amyloid Beta Protein from Brain May Lead to Alzheimer’s Disease
– Johns Hopkins Medicine Team Discovers Novel Mediator of Once Mysterious Chronic Itch – Study Suggests Molecular Changes in Tissue Microenvironment May Promote Colorectal Cancer
– Researchers ID Anti-Inflammatory Proteins as Therapy Targets for Nasal and Sinus Problem
– Johns Hopkins Children’s Center Receives NIH Award to Study Dangerous Pediatric Disease

Good afternoon, the FDA today approved aducanumab–the first new therapy for Alzheimer’s in 13 years. University of Miami expert Dr. James Galvin would be great for an interview.

Good afternoon, the FDA today approved aducanumab–the first new therapy for Alzheimer’s in 13 years. University of Miami experts, Including Dr. James Galvin, led clinical trials to test the pioneering drug with patients and can discuss why the aducanumab is…

Renowned Alzheimer’s Clinical Trials Researcher Available to Comment on June 7 FDA Approval of Aducanumab

The Food and Drug Administration on June 7 approved Aducanumab, which will carry the brand name Aduhelm, as the first new treatment for Alzheimer’s disease in nearly 20 years. Dr. Jeffrey L. Cummings, UNLV research professor and leading expert on Alzheimer’s clinical trials, calls…

FAU’s Ruth Tappen Named ‘2021 Alliance World Class Faculty’ Honoree

Ruth M. Tappen, Ed.D., RN, FAAN, the Christine E. Lynn Eminent Scholar and professor in FAU’s Christine E. Lynn College of Nursing, is nationally and internationally renowned as an innovative researcher and scholar. Tappen was recently recognized as the “2021 Alliance World Class Faculty” honoree by the Greater Fort Lauderdale Alliance.

New research may offer hope for Alzheimer’s patients

University of Kentucky Neuroscience Professor Greg Gerhardt’s new research program will provide answers to long-standing questions about the role of neurotransmitters GABA and glutamate in the progression of Alzheimer’s disease. A culmination of his nearly 40 years of brain research, Gerhardt’s study could help to develop new treatments for the disease.

Secondary infections inflame the brain, worsening cognition in Alzheimer’s disease

New research into Alzheimer’s disease (AD) suggests that secondary infections and new inflammatory events amplify the brain’s immune response and affect memory in mice and in humans – even when these secondary events occur outside the brain. Scientists believe that…

Alzheimer’s disease raises the risk of severe COVID-19 and death from this viral disease

Patients with dementia and especially Alzheimer’s run a threefold risk of dying as a result of infection by SARS-CoV-2. The risk is six times greater if they are over 80, according to a study by Brazilian researchers

Rush Researchers Develop New Measure of Brain Health

A new measure of brain health developed by researchers at Rush University Medical Center may offer a novel approach to identifying individuals at risk of memory and thinking problems, according to research results published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association on June 1.

Novel approaches in treating neurodegenerative disorders

The central nervous system (CNS) is the most vital component of our body, regulating various kinds of daily activities that are essential for our life processes. Keeping the balance between body and brain and maintaining the homeostasis of CNS is…